JP Morgan Chase Portfolio holdings
JPMorgan Chase & Co., formed by the 2000 merger of J.P. Morgan & Co. and Chase Manhattan Bank, is a global financial services giant headquartered in New York City, tracing its roots back to 1799 through its predecessor firms. As one of the largest banks in the world, it operates across investment banking, commercial banking, asset management, and consumer banking, managing trillions in assets and serving millions of customers, corporations, and governments. Led by CEO Jamie Dimon since 2005, the firm is renowned for its role in high-profile deals, robust trading operations, and its Chase retail banking network, which includes extensive credit card and mortgage services. Combining a legacy of financial innovation with a dominant market presence, JPMorgan Chase remains a cornerstone of the global economy.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
JPMorgan BetaBuilders Europe ETF
BBEU
|
+$4.02B |
| 2 |
iShares US Treasury Bond ETF
GOVT
|
+$3.55B |
| 3 |
Eli Lilly
LLY
|
+$2.61B |
| 4 |
Amphenol
APH
|
+$2.33B |
| 5 |
TotalEnergies
TTE
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard S&P 500 ETF
VOO
|
+$9.67B |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$7.48B |
| 3 |
Meta Platforms (Facebook)
META
|
+$7.25B |
| 4 |
NVIDIA
NVDA
|
+$6.05B |
| 5 |
Microsoft
MSFT
|
+$5.54B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.15% |
| 2 | Miscellaneous | 24.97% |
| 3 | Financials | 9.75% |
| 4 | Consumer Discretionary | 8.78% |
| 5 | Healthcare | 7.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
2951
Argan
AGX
$5.39B
| $6.83M | ﹤0.01% |
21,790
-627
| -3% | -$199K |
2013 Q2
50 quarters
|
|
2952
Twist Bioscience
TWST
$12.5B
| $6.82M | ﹤0.01% |
215,147
-803,087
| -79% | -$25.1M |
2018 Q4
28 quarters
|
|
2953
Fidelity MSCI Health Care Index ETF
FHLC
$3.39B
| $6.82M | ﹤0.01% |
91,804
+11,166
| +14% | +$804K |
2017 Q3
33 quarters
|
|
2954
Valvoline
VVV
$3.9B
| $6.81M | ﹤0.01% |
234,431
-23,650
| -9% | -$759K |
2016 Q3
37 quarters
|
|
2955
Seacoast Banking Corp of Florida
SBCF
$3.16B
| $6.81M | ﹤0.01% |
216,762
-31,491
| -13% | -$981K |
2016 Q4
36 quarters
|
|
|
EFXT
2956
Enerflex
EFXT
$3B
| $6.78M | ﹤0.01% |
439,652
+80,218
| +22% | +$1.07M |
2024 Q1
7 quarters
|
|
2957
Ooma
OOMA
$574M
| $6.76M | ﹤0.01% |
576,041
+22,125
| +4% | +$252K |
2017 Q3
33 quarters
|
|
2958
SK Telecom
SKM
$14.1B
| $6.74M | ﹤0.01% |
328,353
+327,945
| +80,379% | +$6.73M |
2013 Q2
50 quarters
|
|
2959
First Financial Bankshares
FFIN
$4.61B
| $6.72M | ﹤0.01% |
225,023
-247,534
| -52% | -$7.8M |
2013 Q2
50 quarters
|
|
2960
Invesco Aerospace & Defense ETF
PPA
$7.41B
| $6.72M | ﹤0.01% |
42,879
+1,777
| +4% | +$274K |
2021 Q2
18 quarters
|
|
2961
Olema Pharmaceuticals
OLMA
$719M
| $6.71M | ﹤0.01% |
268,471
+238,340
| +791% | +$4.24M |
2020 Q4
20 quarters
|
|
2962
PUT
Honeywell
HON
$67.8B
| $6.7M | ﹤0.01% |
34,325
-1,643
| -5% | -$321K |
2021 Q2
18 quarters
|
|
2963
Intellia Therapeutics
NTLA
$1.72B
| $6.69M | ﹤0.01% |
743,698
+303,126
| +69% | +$4.17M |
2017 Q4
32 quarters
|
|
2964
iShares Bloomberg Roll Select Commodity Strategy ETF
CMDY
$702M
| $6.68M | ﹤0.01% |
137,128
+12,418
| +10% | +$660K |
2023 Q3
9 quarters
|
|
2965
Ocular Therapeutix
OCUL
$1.53B
| $6.68M | ﹤0.01% |
550,269
+274,109
| +99% | +$3.33M |
2017 Q1
35 quarters
|
|
2966
Kura Sushi USA
KRUS
$505M
| $6.67M | ﹤0.01% |
127,441
+124,272
| +3,921% | +$6.78M |
2019 Q3
25 quarters
|
|
2967
Biohaven
BHVN
$1.94B
| $6.66M | ﹤0.01% |
589,565
-745,890
| -56% | -$9.24M |
2022 Q4
12 quarters
|
|
2968
iShares Core Dividend ETF
DIVB
$1.99B
| $6.64M | ﹤0.01% |
124,948
+2,131
| +2% | +$112K |
2022 Q4
12 quarters
|
|
2969
Direxion Daily 20+ Year Treasury Bull 3X ETF
TMF
$1.87B
| $6.63M | ﹤0.01% |
177,772
+16,774
| +10% | +$679K |
2022 Q2
14 quarters
|
|
2970
PUT
Northrop Grumman
NOC
$67.9B
| $6.61M | ﹤0.01% |
11,600
| – | – |
2024 Q3
5 quarters
|
|
2971
Hartford Municipal Opportunities ETF
HMOP
$754M
| $6.61M | ﹤0.01% |
168,915
+55,992
| +50% | +$2.19M |
2023 Q3
9 quarters
|
|
|
QXO
2972
QXO Inc
QXO
$12.5B
| $6.61M | ﹤0.01% |
342,448
-24,636
| -7% | -$472K |
2024 Q3
5 quarters
|
|
2973
BioCryst Pharmaceuticals
BCRX
$2.09B
| $6.58M | ﹤0.01% |
843,370
-289,007
| -26% | -$2.09M |
2017 Q4
32 quarters
|
|
2974
Fulgent Genetics
FLGT
$591M
| $6.57M | ﹤0.01% |
250,128
-48,886
| -16% | -$1.27M |
2020 Q2
22 quarters
|
|
2975
JPMorgan Active China ETF
JCHI
$13.9M
| $6.57M | ﹤0.01% |
120,000
-70,000
| -37% | -$4M |
2023 Q1
11 quarters
|
|
Similar funds
JP Morgan Chase's Q4 2025 Portfolio in Review
As of Q4 2025, JP Morgan Chase held 7,944 positions worth $1.59T, down 4.6% from $1.67T the previous quarter. Its ten largest holdings account for 26% of the portfolio.
JP Morgan Chase withdrew a net $106B in Q4 2025, closing 563 positions and reducing 3,329 holdings. Its most notable exit was Interpublic Group of Companies, an estimated $228M position sold in full.
By sector, the portfolio is most concentrated in Technology at 25% of assets, down from 26% a quarter earlier, followed by Miscellaneous and Financials.
Against the trend, JP Morgan Chase opened a new position in Quadratic Interest Rate Volatility and Inflation Hedge ETF worth $99.9M.
- JP Morgan Chase's largest Q4 2025 buy was Quadratic Interest Rate Volatility and Inflation Hedge ETF: 5,216,227 shares worth $99.9M.
- JP Morgan Chase added most to JPMorgan BetaBuilders Europe ETF in Q4 2025, an estimated $4.02B increase.
- JP Morgan Chase's biggest Q4 2025 reduction was Vanguard S&P 500 ETF, cutting an estimated $9.67B.
- JP Morgan Chase fully exited Interpublic Group of Companies in Q4 2025, selling an estimated $228M.
- JP Morgan Chase's ten largest holdings make up 26% of its $1.59T portfolio in Q4 2025.
- JP Morgan Chase opened 577 new positions and closed 563 in Q4 2025.
- JP Morgan Chase's portfolio value fell 4.6% quarter-over-quarter to $1.59T.
Based on JP Morgan Chase's 13F filing for Q4 2025, filed 11 Feb 2026.